Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 35,202 | 30,872 | 189,564 | 63,731 | 33,750 |
| Cost of Goods | 836 | 3,052 | 7,488 | 8,332 | 7,788 |
| Gross Profit | 34,366 | 27,820 | 182,076 | 55,399 | 25,962 |
| Operating Expenses | 55,275 | 51,584 | 56,635 | 47,654 | 52,228 |
| Operating Income | -20,073 | -23,712 | 125,929 | 8,077 | -25,478 |
| Interest Expense | 4,770 | 5,230 | 5,458 | 5,538 | 5,540 |
| Other Income | 1,983 | 1,668 | 1,080 | 790 | 435 |
| Pre-tax Income | -22,860 | -27,274 | 121,551 | 3,329 | -30,583 |
| Income Tax | 33 | 187 | -2,331 | 580 | 180 |
| Net Income Continuous | -22,893 | -27,461 | 123,882 | 2,749 | -30,763 |
| Net Income | $-22,893 | $-27,461 | $123,882 | $2,749 | $-30,763 |
| EPS Basic Total Ops | -0.16 | -0.19 | 0.93 | 0.02 | -0.23 |
| EPS Basic Continuous Ops | -0.16 | -0.19 | 0.93 | 0.02 | -0.23 |
| EPS Diluted Total Ops | -0.16 | -0.19 | 0.92 | 0.02 | -0.23 |
| EPS Diluted Continuous Ops | -0.16 | -0.19 | 0.92 | 0.02 | -0.23 |
| EBITDA(a) | $-19,754 | $-23,276 | $127,974 | $8,417 | $-24,862 |